It has long been known that CD4 T cells are necessary to provide help to B cells, triggering a germinal centre (GC) reaction where affinity maturation and isotype switching occur. However, the nature of the dedicated CD4 helper T cells, known as T follicular helper (Tfh), was only recently described. Here, we review the biology and function of the recently described T follicular regulatory (Tfr) cells, another CD4 T-cell population also found within GCs but with regulatory function and characteristics. Tfr cells have been identified in mice and humans as simultaneously presenting characteristics of T follicular cells (namely CXCR5 expression) and regulatory T cells (including Foxp3 expression). These Tfr cells have been implicated in the regulation of the magnitude of the GC reaction, as well as in protection from immune-mediated pathology.
Introduction
Germinal centres (GCs) are secondary lymphoid structures within B-cell follicles where B cells go through affinity maturation (somatic hypermutation and positive selection) and class-switch recombination to generate high-affinity antibodies. 1 For B cells to undergo these processes, they require the help of T follicular helper (Tfh) cells, a specialized CD4 + T-cell subset that provides survival, proliferation and selection signals by engaging in cognate interactions with B cells. 2 Moreover, Tfh cells also produce important cytokines for the GC reaction, namely interleukin-21 (IL-21) and IL-4. 2 Another CD4 + T-cell population has been recently described as present in GCs, the T follicular regulatory (Tfr) cell population. The Tfr cells are a subset of forkhead box P3 positive (Foxp3 + ) regulatory T (Treg) cells that acquire a follicular phenotype and migrate into GCs, where they act as regulators of the GC reaction on multiple levels. [3] [4] [5] The importance of Treg cells for the control of antibody responses has been long known. Indeed, one of the consequences of the absence of Treg cells is the increased level of circulating antibodies, namely IgG and IgE, which originate in GCs. 6, 7 Further studies showed that Treg cells are capable of controlling antibody responses by inhibiting activation-induced cytidine deaminase expression and class-switch recombination, and by directly killing B cells. [8] [9] [10] Also, CXC chemokine receptor type 5 positive (CXCR5 + ) Treg cells could be found within GCs of immunized mice. 11 However, the confirmation of the existence of a specialized subset of Treg cells, which migrates into GCs and controls antibody responses, came with the identification of the Tfr cell population by three independent groups. [3] [4] [5] These studies, performed in mouse models, described a population with mixed characteristics of Treg and Tfh cells. [3] [4] [5] Tfr cells express not only the Treg master regulator Foxp3 but also other Treg-related molecules such as CD25, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), glucocorticoidinduced tumour necrosis factor receptor-related protein, and granzyme B. In addition, Tfr cells express Tfh cellassociated molecules including CXCR5, inducible T-cell Abbreviations: Bcl-6, B-cell lymphoma 6; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CXCR5, CXC chemokine receptor type 5; DC, dendritic cell; Foxp3, forkhead box P3; GC, germinal centre; ICOS, inducible T-cell co-stimulator; IL, interleukin; NFAT2, nuclear factor of activated T cells 2; NP, 4-hydroxy-3-nitrophenyl; PD-1, programmed cell death 1; PD-L1, PD-1 ligand 1; Tconv, conventional CD4 + T; TCR, T-cell receptor; Tfh, T follicular helper; Tfr, T follicular regulatory; TGF-b, transforming growth factor b; TRAF3, tumour necrosis factor receptor-associated factor 3; Treg, regulatory T
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co-stimulator (ICOS), programmed cell death 1 (PD-1), signalling lymphocytic activation molecule-associated protein, and, importantly, the master transcription factor of both Tfh and Tfr cells B-cell lymphoma 6 (Bcl-6). Hence, Tfr cells present, simultaneously, the characteristics of both Treg and Tfh cells by maintaining a suppressive function and gaining ability to access B-cell follicles and GCs.
Tfr cells have been described in mice and humans: one of the first reports describing Tfr cells demonstrated the presence of these cells within GCs of human tonsils. 3 However, as for Tfh cells, the difficulty in obtaining human samples of secondary lymphoid tissues has led to most of the work being performed in mice. Nevertheless, several recent studies have investigated a population of CXCR5 + Foxp3 + CD4 + T cells from human blood, considered to be circulating Tfr cells, in samples from patients with autoimmunity or infectious diseases.
The initial studies describing Tfr cells described several key characteristics of this population, namely Tfr ability to regulate GC reactions. Further studies, in mice and human samples, have complemented our knowledge regarding Tfr function, origin, repertoire and specificity, as well as the regulatory mechanisms employed. Nevertheless, as most of the studies have been performed in mouse models, whether human Tfr cells have the same characteristics awaits confirmation. A brief summary of the known characteristics and markers used to identify Tfr cells in mice and humans can be found in Table 1 .
The biology of Tfr cells
The differentiation of Tfr cells is still not as characterized as the differentiation of Tfh cells. Nevertheless, Tfr cells seem to undergo a multi-step differentiation process similar to Tfh cells (Fig 1) . For Tfh cells, such multistep priming is initiated, as for other CD4 + T-cell subsets, following antigen recognition on dendritic cells. For the subsequent step, cognate interactions with B cells are required for full Tfh differentiation and expansion. 2, 12, 13 The same priming requirements were demonstrated for Tfr cells, which were substantially reduced in immunized mice where dendritic cells had been ablated. 14 The full differentiation of Tfr cells is also dependent on interactions with B cells. Indeed, Tfr cells are almost absent in draining lymph nodes of immunized mice that lack B cells.
14 However, these mice still contain a population of circulating Tfr cells upon immunization.
14 Hence, this population of blood Tfr cells originates upon the initial interaction with dendritic cells and before full commitment to the GC fate. The same study also showed that circulating Tfr cells can persist for long periods of time, representing a pool of cells that can later be recruited into the GC to suppress subsequent responses. 14 Another similarity between the differentiation processes of Tfr and Tfh cells is the requirement of cognate signalling through the T-cell receptor (TCR) and co-stimulatory signals through CD28 and ICOS. 4, [15] [16] [17] The CD28 requirement for Tfr cell commitment was first shown with bone marrow chimeras, containing a mixture of CD28-deficient and CD28-sufficient cells, where Tfr and Tfh cells originated exclusively from CD28-sufficient precursors. 4 These results were later corroborated by a study showing the absence of Tfr and Tfh cells in CD28-deficient and in ICOS-deficient mice. 17 There are, however, some differences between the differentiation processes of Tfr and Tfh cells. A striking difference is that only the differentiation of Tfr cells seems to be affected by co-inhibitory signals. Although PD-1 is equally expressed by Tfr and Tfh cells, PD-1-deficient mice display an increased number of Tfr cells whereas the Tfh population remains unaffected. 17 The authors further established that the negative effect of PD-1 in Tfr cells is dependent on binding of PD-1 ligand 1 (PD-L1), but not PD-L2, since only PD-L1-deficient mice could replicate the Tfr phenotype observed in PD-1-deficient mice. Another inhibitory molecule that has a negative impact on Tfr cell differentiation and function is CTLA-4. Using mouse strains where CTLA-4 was conditionally deleted on Foxp3 + Treg cells, two groups simultaneously demonstrated that, under those conditions, the suppressive capacity Tfr cells and their ability to control B-cell responses were diminished even though there was an increase of total Tfr cell numbers. 18, 19 Similar results were reported following CTLA-4 targeting with a blocking antibody. 18 The cytokine IL-21 also has a negative impact on Tfr cell numbers even though it supports Tfh differentiation. 20, 21 Interleukin-21 induces Bcl-6 expression, which, in turn, limits CD25. The reduction of CD25 expression then leads to lower responsiveness to IL-2 that, consequently, has a negative impact on the proliferation of Tfr cells. . At day 7, the now mature GC has increased in size due to fast cell proliferation and it can be divided into two zones: the dark and light zones. The dark zone is mainly composed of rapidly dividing B cells, whereas in the light zone other cell types like Tfh and FDCs can be found. Tfr cells start to accumulate in the GC at this point, however, besides also requiring priming by DCs, the differentiation mechanism and required signals are still not well understood. There are also similarities and differences in the transcription factors involved in Tfr and Tfh cell differentiation. As referred above, Bcl-6 is the master regulator for both subsets. 3, 4, 22 Signal transducer and activator 3 is also required by both Tfr and Tfh populations but, although Tfh numbers are reduced in mice where signal transducer and activator 3 was conditionally deleted on CD4 + T cells, Tfr differentiation is almost abrogated in those mice. 23, 24 A key difference on the transcription factors present in Tfr and Tfh cells is the balance between Bcl-6 and Blimp-1. 4 Whereas Tfh cells only express Bcl-6, Tfr cells express, simultaneously, both mutual antagonists and repressors Bcl-6 and Blimp-1. 4 It has been suggested that, while Bcl-6 is important to acquire a Tfh-like phenotype by Tfr cells, Blimp-1 may be necessary for the Treg-like suppressive function of Tfr cells. 4 Another difference is that CXCR5 expression in both subsets seems to have a distinct regulation. Tfh cells require achaete-scute homologue-2 for initial CXCR5 expression. 25 Tfr cells, however, do not express achaete-scute homologue-2 and appear to rely on nuclear factor of activated T cells 2 (NFAT2) to express CXCR5. 25, 26 Indeed, NFAT2 was shown to bind to the CXCR5 promoter and induce its transcription, and Tfr cell numbers are reduced in NFAT2-deficient mice. In addition, the tumour necrosis factor receptor-associated factor 3 is only important for Tfr differentiation and function, and is involved in the regulation of ICOS in Treg cells. 27 Therefore, Treg-conditional tumour necrosis factor receptor-associated factor 3-deficient mice have impaired Tfr cell differentiation. 27 The temporal accumulation of Tfr and Tfh cells in the GC is also different. Although the same type of cellular interactions seems to trigger both Tfr and Tfh cell differentiation, kinetic studies of the accumulation of both populations after immunization revealed that Tfr cells appear in the GC at later time-points, reaching their maximum frequency around 5 days later than Tfh cells do (Fig 1) . 5, 28 This unsynchronized accumulation of Tfr and Tfh cells may be required for the initial establishment of the GC, where few Tfh and GC B cells need to rapidly expand without the suppressive action of Tfr cells. On the contrary, once the GC has reached a significant size, Tfr cells would be important for the control of the GC reaction and its outcome.
The origin and specificity of Tfr cells are two other features that have been addressed in several studies. The first three studies describing Tfr cells reported that these cells derived from thymic Treg cells. [3] [4] [5] Linterman et al. observed that antigen-specific TCR-transgenic CD4 + cells, which do not contain thymic Treg cells, did not differentiate into Tfr cells (even though they readily gave rise to Tfh cells). 4 Our group used T-cell-deficient mice as recipients of antigen-specific TCR-transgenic CD4 + cells and thymic Treg cells to demonstrate that only the thymic (Fig 2) . 30 Moreover, we found that GCs from immunized mice contained Tfh cells stained with an appropriate MHC class II tetramer, whereas Tfr cells from the same GCs did not bind the tetramer. 30 Indeed, we could not detect antigen-specific tetramer-positive Tfr cells in any of the conditions tested. Furthermore, sorted Tfr cells did not preferentially proliferate or survive in vitro with immunizing antigen signals when compared with a control antigen. Finally, we sequenced the TCR-a-chain (TRA gene) of Tfr, Tfh and Treg cell populations from immunized TCR-b-restricted mice. The repertoire analysis showed that, although Tfr cells are an oligoclonal population, they have a repertoire that resembles the repertoire of Treg cells, but that is different from that of Tfh cells. 30 Hence, our work showed that the TCR repertoire of Tfh and Tfr cells from the same GCs are considerably different: 30 Tfh cells bear TCRs specific for the immunizing antigen, but the TCR repertoire of Tfr cells lacks those antigen-specific clones while being similar to the predominantly self-reactive repertoire of thymic Treg cells (Fig 2) .
Tfr cell regulatory mechanisms
Tfr cells constitute a regulatory T-cell subset specialized in the control of the GC response. The initial studies that described Tfr cells already showed that this population controls the GC size and the amount of antibodies produced. [3] [4] [5] Indeed, in the absence of Tfr cells, the size of the GC detected by immunofluorescence was increased, 5 as well as the total numbers of Tfh and GC B cells. [3] [4] [5] In the same line, the amount of antigen-specific IgM and IgG antibodies was higher in the serum of immunized mice lacking Tfr cells. 3, 5 Another feature that has been studied is the impact of Tfr cells in the affinity of the antibodies produced. Chung et al. reported that Tfr cells led to reduced antibody affinity. 3 This conclusion was obtained by observing lower levels of high affinity 4-hydroxy-3-nitrophenyl (NP)-specific antibodies in T-cell-deficient mice, immunized with NP conjugated to a protein, that had received wild-type CD4 + naive T and Bcl-6-deficient Foxp3 + Treg cells when compared with mice that had received wild-type Foxp3 + Treg and naive CD4 + T cells. Two other studies, however, 31 The authors co-transferred naive CD4 + T cells with Bcl-6-deficient or Bcl-6-sufficient CD25 + Treg cells into T-cell-deficient mice, and verified that IgA produced in Peyer's patches from mice lacking Tfr cells had lower affinity and diversity. In the other study, Sage et al.
showed that, when the action of Tfr cells is compromised by Treg-conditional deletion of CTLA-4, the amount of antibodies produced was higher, but the affinity generated (measured as the ratio between high-and low-affinity NPspecific antibodies on mice immunized with NP-ovalbumin) was lower. 19 This possible effect on antibody affinity could be explained by the facilitated help from Tfh cells to B cells in the absence of Tfr cells, and consequent generation of low-affinity plasma cells. 32 The impact of Tfr cells on the GC reaction seems to be due to its direct action on Tfh and GC B cells. Tfh cells cultured in the presence of Tfr cells express lower levels of Ki-67 and produce less IL-4 and IL-21, indicating a suppressive impact of Tfr cells on Tfh proliferation and cytokine production.
14 In addition, in the absence of Tfr and Treg cells (by transiently depleting Foxp3 + cells 6 days after immunization), there is a reduction of GC B cells specific for the dominant epitope of the immunizing antigen, so implicating Tfr cells in the regulation of non-antigen-specific B-cell clones in the GC. 4 Whether this impact was due to a direct effect of Tfr cells on GC B cells or a consequence of less regulation of Tfh clones by Tfr cells leading to greater 'uncontrolled' help to B cells was not addressed.
CTLA-4 is the only molecule expressed by Tfr cells so far described as a direct mediator of Tfr cell suppressive function. 18, 19 As referred previously, in the absence of CTLA-4 on Treg cells, there is an increase in the Tfr cell numbers, but those Tfr cells lose most of their suppressive capacity. 18, 19 At least part of the suppressive mechanism of Tfr cells seems to involve the modulation of Tfh and GC B cells metabolism. 33 Indeed, in in vitro co-cultures, Tfr cells induce a suppressive state on Tfh and GC B cells, especially at metabolic level (i.e. glucose uptake, glycolysis and onecarbon metabolism), that persists in the absence of Tfr cells and is associated with epigenetic changes. 33 This suppressive effect translates in the inhibition of class-switch recombination and antibody production by B cells, and IL-21 and IL-4 production by Tfh cells. The suppressive state is reversible, as it can be abrogated in the presence of high levels of IL-21, which acts directly on both B cells (restoration of B-cell activation) and Tfr cells (inhibition of proliferation). 33 In fact, this observation is in line with IL-21 specifically rendering Tfr cells less responsive to IL-2, in both mice and humans, and, consequently, having a negative impact on the proliferation of Tfr cells. 20 Despite the fact that most of the suppressive capacity of Tfr cells is lost in the absence of CTLA-4, it is expected that these cells employ multiple and complementary regulatory mechanisms, as has been described for Treg cells. [34] [35] [36] Several mechanisms have been proposed that involve: (i) the secretion of the regulatory cytokines IL-10 and transforming growth factor b (TGF-b); (ii) the induction of cell death by secretion of granzyme B; (iii) displacement of Tfh cells from GC B-cell surface; and (iv) interaction with Tfh and/or GC B cells through a still unknown receptor. 37 Although IL-10 is regarded as a suppressive cytokine, evidence seems to exclude the production of IL-10 by Tfr cells as a regulatory mechanism of the GC reaction. Tfr cells produce IL-10, but high amounts of this cytokine were detected in the supernatants of Tfh and GC B-cell cultures when Tfr cells were not present.
14 Indeed, and contrary to what would be expected, Tfr cells seem to inhibit IL-10 production; however, IL-10 inhibition may still be in agreement with Tfr cell suppressive functions, as IL-10 is important for GC B-cell survival and proliferation. 14, 38 The production of TGF-b may be an additional mechanism of Tfr suppression, as Tfh cells are suppressed by this cytokine. 39 Tfr cells also express granzyme B, 8, 9 Upon activation, this subset up-regulated CXCR5, acquiring the capacity to migrate towards CXCL13-enriched GC. In their in vitro assays, Lim et al. demonstrated that these cells suppressed classswitch recombination by B cells, as they inhibited immunoglobulin production and activation-induced cytidine deaminase expression. Those earlier observations gained a new importance following the identification of Tfr cells as a specialized cell subset. [3] [4] [5] Since their discovery, Tfr cells have been regarded as putative important players in the pathogenesis of human diseases characterized by disrupted GC responses, like autoimmune and chronic infectious diseases ( 40 Similar to findings in mice, there is evidence suggesting some divergence in differentiation of human Tfr and Tfh cells: a primary immunodeficiency defined by PI3KR1 gain-of-function mutation did not affect the frequency of tonsil Tfr cells, but it significantly reduced the frequency of Tfh cells. 41 Tfr cells, as well as Tfh cells, play their functional role in B-cell follicles and GC in secondary lymphoid tissues. The restricted access to human tissues forced the search for these cells in human blood. Several studies confirmed circulating CXCR5 + T cells as the counterparts of tissue Tfh cells, arising from lymphoid tissue cells before reaching the GC, in spite of low Bcl-6 expression. [42] [43] [44] [45] [46] It is well known that some human blood Treg cells express CXCR5 among other CXC chemokine receptors. 47 Hence, many studies have been using circulating CXCR5 + Foxp3 + T cells to define Tfr cells in humans (Box 1).
48-53 Surprisingly, no study specifically addressed whether blood CXCR5 + Foxp3 + T cells are truly circulating Tfr cell counterparts. Although circulating memory Tfr cells were observed after immunization protocols in mice, 14, 17 CXCR5 and Foxp3 transient up-regulation upon human T-cell activation challenged the assumption that human blood CXCR5 + Foxp3 + T cells are Tfr cells. 
Tfr cells in different human diseases

Autoimmune diseases
A disturbed B-T-cell interaction can be responsible for the generation of self-reactive antibodies in autoimmune diseases. 60 Although Tfh cells are indispensable for GC formation and generation of high-affinity antibodies, Tfh and Tfr cells are still poorly understood in human autoimmunity, mostly because of difficult access to the lymphoid tissues where those populations operate. Tfr cells are particularly attractive to study in the setting of autoimmunity as their modulation may have therapeutic potential.
Few studies have addressed Tfr cells in human autoimmunity (Table 2 ). Blood CXCR5 + PD-1 + CD25 + CD127
À Tfr cells were reduced in patients with multiple sclerosis. 50 In addition, blood Tfr cells from patients with multiple sclerosis were less suppressive than equivalent cells sorted from healthy controls, using CD25 À CD127 + T cells as responders in vitro. 50 This work suggests that blood Tfr cells might be functionally defective in autoimmunity. However, the functional assays performed in this study did not evaluate the putative specialization of Tfr cells in the suppression of humoral responses. An additional study also found a decreased frequency of blood CXCR5 + Foxp3 + Tfr cells in untreated patients with myasthenia gravis, recovering to normal levels after corticosteroid-based treatment. 52 However, not all studies of CXCR5 + Foxp3 + T cells in autoimmunity are concordant. A higher frequency of blood CXCR5 + Foxp3 + Tfr cells was found in patients with ankylosing spondylitis, increasing even further after treatment with Etanercept. 61 The blood frequency of Tfr cells did not correlate with disease severity of multiple sclerosis or ankylosing spondylitis, questioning the direct role of blood CXCR5 + Foxp3 + T cells in autoimmune pathogenesis. Besides organ-specific autoimmune diseases, it would be important to assess Tfr cells in systemic autoimmune diseases, where potentially more severe tolerance disruption mechanisms are operating. We found that blood Tfr cell frequency is increased in patients with Sj€ ogren syndrome. 59 Therefore, our data suggest that blood Tfr cells, as well as the Tfr : Tfh cell ratio, may constitute markers of disturbed GC responses in human autoimmunity. À CXCR5 + CD4 + T cells for peripheral blood) were also increased, suggesting that Tfr and Tfh cell expansion could occur simultaneously in cases of antigen persistence. Consistently, in vitro studies using tonsil cells spinoculated with X4 and R5 HIV have shown Tfr cell expansion (with increased CTLA-4, lymphocyte-activation gene 3 (LAG-3) and IL-10 expression) upon HIV infection in a TGF-dependent manner. 62 In blood, the presence of broad neutralizing antibodies did not impact the frequency of Tfr cells, although patients with high titres of neutralizing antibodies displayed a higher expression of PD-1 in Tfr cells. 64 Although increased PD-1 signalling has been shown to inhibit Tfr cell function in mice, 17 it is still speculative to correlate the presence of broad neutralizing antibodies with putative Tfr cell exhaustion.
HIV and other infectious diseases
Blood CXCR5 + Foxp3 + Tfr cells were also found increased in hepatitis B virus and hepatitis C virus chronically infected patients, showing a significant correlation with blood viral load in both infections. An 
Conclusions
The GC reaction is a key event in humoral responses. The B-cell-Tfh cell interactions are important for the production of high-affinity protective antibodies, following B-cell receptor hypermutation and selection. However, immune dysregulation may lead to autoantibody production and autoimmunity. 
